To read the full story, subscribe or sign in.

Gemin X Can Take Lead Drug Through Phase II With $65M

Last updated: Oct. 19, 2019

Raising $65.2 million in its largest financing to date, Gemin X Biotechnologies Inc. plans to advance its lead oncology candidate through Phase II studies. (BioWorld Today)

BioWorld

Accuracy, utility of COVID-19 lateral flow tests questioned in the U.K.

BioWorld MedTech

LONDON – A huge row has broken out in the U.K. about the accuracy and utility of COVID-19 lateral flow tests (LFT) in screening asymptomatic people, as a pilot...

Israel continues to shine as hub of med-tech innovation

BioWorld MedTech

In recent years, Israel has proven to be a hot spot for med-tech innovation. The country boasts more than 1,500 companies in the health care and life sciences...

Today's news in brief

BioWorld

BioWorld briefs for Jan. 15.

Sarepta DMD phase II hangs in ‘balance’ as disparity in North Star leads astray

BioWorld

Sarepta Therapeutics Inc.’s miss on a key phase II ambulatory endpoint in its Duchenne muscular dystrophy (DMD) trial may have been caused by a dramatic disparity...

Sinovac’s COVID-19 vaccine more than 78% effective in Brazil trials

BioWorld

CAJICA, Colombia – Brazil's Butantan Institute and the government of the state of Sao Paulo released efficacy results on Jan. 7 for Coronavac, developed by...